Breaking News Instant updates and real-time market news.

KFY

Korn/Ferry

$30.46

-0.1498 (-0.49%)

, GSK

GlaxoSmithKline

$41.50

0.16 (0.39%)

13:44
02/21/17
02/21
13:44
02/21/17
13:44

Korn Ferry Futurestep partners with GlaxoSmithKline over talent acquisition

Futurestep division of Korn Ferry (KFY) has been appointed by GlaxoSmithKline (GSK) to provide a Flexible Delivery Solution for recruitment support across the United Kingdom, United States and Latin America. In a desire to better respond to business requirements and to help prepare for future recruitment demand, GSK chose Futurestep to assist with hiring across its Pharmaceutical, Consumer Healthcare and Vaccines business units. Futurestep will deploy a dedicated onsite team of specialist recruiters across key locations. This will be complemented by dedicated sourcing and screening hubs within Futurestep's Warsaw, Manchester, Bangalore and Dallas Talent Delivery Centres.

KFY

Korn/Ferry

$30.46

-0.1498 (-0.49%)

GSK

GlaxoSmithKline

$41.50

0.16 (0.39%)

  • 21

    Feb

KFY Korn/Ferry
$30.46

-0.1498 (-0.49%)

08/17/16
DBAB
08/17/16
INITIATION
Target $27
DBAB
Hold
Korn/Ferry initiated with a Hold at Deutsche Bank
Target $27.
08/18/16
08/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Barnes & Noble (BKS) initiated with a Neutral at Sidoti. 2. Digital Ally (DGLY) initiated with a Buy at Maxim. 3. Korn/Ferry (KFY) initiated with a Hold at Deutsche Bank. 4. Phillips 66 Partners (PSXP) initiated with a Buy at Stifel. 5. Arrowhead (ARWR) initiated with a Buy at Cantor. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/09/16
RHCO
09/09/16
NO CHANGE
RHCO
Korn/Ferry showing signs of rebounding, says SunTrust
After Korn/Ferry reported slightly higher than expected Q2 revenue but slightly lower than expected EPS, SunTrust analyst Tobey Sommer says there are signs that demand for the company's services is rebounding. The analyst says that the company's Executive Search unit obtained 25% more new business in North America in August versus July. Sommer expects the company's Futurestep business to remain strong throughout this year. The analyst reiterates a Buy rating on the stock.
02/15/17
RHCO
02/15/17
NO CHANGE
RHCO
Korn/Ferry shares should be bought at current levels, says SunTrust
SunTrust analyst Tobey Sommer says a survey of private executive search firms indicates that their sentiment is improving. Additionally, the analyst remains upbeat on KornFerry's Futurestep business, and Sommer keeps a $34 price target and a Buy rating on the stock.
GSK GlaxoSmithKline
$41.50

0.16 (0.39%)

10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
02/14/17
RBCM
02/14/17
NO CHANGE
RBCM
Gilead data better than expected, says RBC Capital
RBC Capital analyst Michael Yee says that data on Gilead's (GILD) HIV treatment, bictegravir, shows that the drug was more effective than GlaxoSmithKline's (GSK) dolutegravir in treatment-naive HIV patients. The analyst thinks that the data indicates that Gilead's HIV franchise should be valued at $50+ per share, although he warns that data on a GlaxoSmithKline treatment due to next year could pose a threat to Gilead. He keeps an Outperform rating on Gilead.

TODAY'S FREE FLY STORIES

RAVN

Raven

$33.50

1.15 (3.55%)

14:32
11/17/17
11/17
14:32
11/17/17
14:32
Hot Stocks
Raven issued patent for Hawkeye Nozzle Control System »

Raven Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CNX

Consol

$16.50

0.465 (2.90%)

14:30
11/17/17
11/17
14:30
11/17/17
14:30
Options
Far upside call buyer in CNX »

Far upside call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XENE

Xenon Pharmaceuticals

, AMGN

Amgen

$170.77

1.39 (0.82%)

14:29
11/17/17
11/17
14:29
11/17/17
14:29
Periodicals
Xenon higher as CNBC's Tirrell reports on nonaddictive pain medicines »

Six drug companies are…

XENE

Xenon Pharmaceuticals

AMGN

Amgen

$170.77

1.39 (0.82%)

RHHBY

Roche

$28.90

0.165 (0.57%)

BIIB

Biogen

$313.98

3.7 (1.19%)

RGEN

Repligen

$33.73

1.12 (3.43%)

VRTX

Vertex

$147.94

-0.72 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 30

    Nov

  • 30

    Nov

  • 02

    Dec

  • 23

    Dec

  • 03

    Feb

  • 23

    Feb

  • 30

    Apr

  • 17

    May

  • 28

    May

RIO

Rio Tinto

$47.70

0.065 (0.14%)

14:25
11/17/17
11/17
14:25
11/17/17
14:25
Periodicals
Rio Tinto working with advisers on bid for stake in SQM, Bloomberg says »

Rio Tinto has lined up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIAB

Viacom

$23.69

-0.92 (-3.74%)

14:25
11/17/17
11/17
14:25
11/17/17
14:25
Options
Viacom call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
11/17/17
11/17
14:25
11/17/17
14:25
General news
Action Economics Survey results »

Action Economics Survey…

TWX

Time Warner

$88.79

0.7799 (0.89%)

, DIS

Disney

$103.63

0.03 (0.03%)

14:23
11/17/17
11/17
14:23
11/17/17
14:23
Periodicals
'Justice League' grosses roughly $16M in opening day in China, Forbes says »

Warner Bros. (TWX) latest…

TWX

Time Warner

$88.79

0.7799 (0.89%)

DIS

Disney

$103.63

0.03 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
11/17/17
11/17
14:17
11/17/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
11/17/17
11/17
14:16
11/17/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAAS

Pan American Silver

$14.77

-0.12 (-0.81%)

14:00
11/17/17
11/17
14:00
11/17/17
14:00
Conference/Events
Pan American Silver investor and analyst day »

Investor and Analyst Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

TJX

TJX

$70.99

1.93 (2.79%)

14:00
11/17/17
11/17
14:00
11/17/17
14:00
Options
Notable options activity in TJX as shares see strength »

Notable options activity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFSW

PFSweb

$6.80

0.21 (3.19%)

13:59
11/17/17
11/17
13:59
11/17/17
13:59
Hot Stocks
PFSweb rallies after Ancora discloses activist stake »

Ancora Advisors earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$103.86

-0.95 (-0.91%)

13:52
11/17/17
11/17
13:52
11/17/17
13:52
Recommendations
RH analyst commentary  »

RH price target raised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$38.49

1.76 (4.79%)

13:45
11/17/17
11/17
13:45
11/17/17
13:45
Options
Hain Celestial call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEG

PSEG

$51.40

0.015 (0.03%)

13:36
11/17/17
11/17
13:36
11/17/17
13:36
Syndicate
Breaking Syndicate news story on PSEG »

PSEG files $129.1M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$89.05

-0.64 (-0.71%)

13:33
11/17/17
11/17
13:33
11/17/17
13:33
Hot Stocks
Indiana American Water acquires Georgetown Water System for about $6.4M »

Indiana American Water…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COT

Cott Corp.

$16.86

0.36 (2.18%)

13:30
11/17/17
11/17
13:30
11/17/17
13:30
Options
Cott Corp call buying continues »

Cott Corp call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:30
11/17/17
11/17
13:30
11/17/17
13:30
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

CC

Chemours

$52.23

0.705 (1.37%)

13:27
11/17/17
11/17
13:27
11/17/17
13:27
Periodicals
Chemours tells Bloomberg N.C. permit revocation 'unwarranted' »

The comment was issued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

13:25
11/17/17
11/17
13:25
11/17/17
13:25
General news
An exodus from U.S. high yield debt this week »

An exodus from U.S. high…

STBZ

State Bank Financial

$28.69

0.21 (0.74%)

13:25
11/17/17
11/17
13:25
11/17/17
13:25
Conference/Events
State Bank Financial participates in a conference call with SunTrust »

Suntrust Bank Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

HIBB

Hibbett Sports

$14.85

0.8 (5.69%)

13:24
11/17/17
11/17
13:24
11/17/17
13:24
Recommendations
Hibbett Sports analyst commentary  »

Hibbett Sports price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

FL

Foot Locker

$40.18

8.33 (26.15%)

13:23
11/17/17
11/17
13:23
11/17/17
13:23
Recommendations
Foot Locker analyst commentary  »

Foot Locker quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

MS

Morgan Stanley

$48.67

0.065 (0.13%)

13:20
11/17/17
11/17
13:20
11/17/17
13:20
Options
Morgan Stanley calls lead puts 9:1 »

Morgan Stanley calls lead…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:17
11/17/17
11/17
13:17
11/17/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.